Radius Health, a developer of therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases, has updated the terms for its upcoming IPO. Planning to list on the NASDAQ under the symbol RDUS, the company now aims to raise $52 million by offering 6.5 million shares at $8 per share. It previously planned to offer 5 million shares at between $14 and $16 per share. Radius initially filed to go public in November 2012 but withdrew its plans due to poor market conditions. With about $192 million in total to-date VC funding, Radius most recently raised a $43 million financing round at a $200 million valuation in April 2013. The company's existing stockholders include MPM Capital (24.6% pre-IPO stake), F2 Ventures (23.1%), Wellcome Trust (6.9%) and Brookside Capital (6.4%), among others.